The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IMMVF | -60% | -99.89% | -73.36% | -100% |
| S&P | +13.95% | +78.35% | +12.25% | +136% |
Immunovia AB engages in the development of methods for diagnosing complex forms of cancer and autoimmune diseases. Its technology platform, IMMray, focuses on the early diagnosis of cancer, predicts disease progression, and monitors therapeutic responsiveness of cancers. The company was founded by Karl Arne Krister Borrebaeck on May 24, 2007 and is headquartered in Lund, Sweden.
No news articles found for Immunovia Ab (publ).
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.61K | -52.9% |
| Gross Profit | -$2,632.13K | 3.3% |
| Gross Margin | -24802.97% | -12729.4% |
| Market Cap | $19.68M | -39.9% |
| Market Cap / Employee | $1.64M | -54.9% |
| Employees | 12 | 33.3% |
| Net Income | -$3,125.23K | 36.2% |
| EBITDA | -$2,584.85K | -29.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.82M | -47.2% |
| Accounts Receivable | $0.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | 0.0% |
| Short Term Debt | $2.17M | 1367.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -244.49% | -122.7% |
| Return On Invested Capital | -246.56% | -131.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1,758.81K | 1.6% |
| Operating Free Cash Flow | -$1,758.81K | 1.6% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 10.35 | 5.78 | 10.57 | -22.42 | -360.69% |
| Price to Sales | 95.61 | 76.11 | 146.94 | 210.67 | 239.52% |
| Price to Tangible Book Value | 2.35 | 9.66 | 4.78 | 8.99 | 8.39% |
| Enterprise Value to EBITDA | -2.31 | -1.73 | -4.79 | -5.87 | -898.33% |
| Return on Equity | -189.4% | -355.0% | -767.1% | -853.7% | 334.40% |
| Total Debt | $61.54K | $10.95K | $49.00K | $2.17M | 1367.25% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
